This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

Patients with multiple myeloma often develop bone lesions resulting in skeletal-related events (SREs), such as spinal cord compression, vertebral collapse, pathologic fractures and bone pain. Bone ...

Background. A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR T-cell therapy. In 2021 ide-cel became the first FDA-approved CAR T ...

This month’s LabRoots discussion titled “Laboratory Screening for Multiple Myeloma: A Nudge in the Direction of Guideline Compliance”, is hosted by Dr. Hart who will discuss a clinical focus on Plasma ...